Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...

It turned down Pfizer’s Staquis (crisaborole) – also sold as Eucrisa in some markets including the US – as a second-line treatment for mild to moderate atopic dermatitis, and Celgene’s ...